文献速递慢性肾脏病

新型荧光肾小球滤过率示踪剂relmapirazin(MB-102)的临床验证

Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102).
PubMed 文献 · Kidney Int · 2024-07-02

本研究在120例肾功能从正常至CKD 4期的成人中,比较新型荧光示踪剂relmapirazin与碘海醇测量的血浆肾小球滤过率(GFR)。两种示踪剂测得的GFR呈近乎完美的线性相关(r²=0.99),Bland-Altman分析显示一致性良好,且relmapirazin测得的GFR不受CKD分期和种族影响,尿中回收率不低于碘海醇,未报告严重不良事件。

要点

  • relmapirazin与碘海醇测得的GFR高度一致(r²=0.99,偏差-0.7 mL/min)。
  • relmapirazin的GFR测定不受CKD分期和种族影响。
  • 尿中relmapirazin回收率不低于碘海醇,未报告严重不良事件。

核心结论

  • relmapirazin可作为人体GFR示踪剂使用。

研究设计与样本

  • 在三个临床中心纳入120例成人,eGFR范围从正常至CKD 4期。
  • 连续静脉推注relmapirazin和碘海醇,随后12小时内系列采血。
  • 采用标准二室药代动力学模型测定血浆GFR,并收集12小时尿液测定回收率。

主要发现

  • 两种示踪剂测得的GFR呈近乎完美线性相关(r²=0.99)。
  • Bland-Altman分析显示一致性良好(一致性界限-7.0至+5.6 mL/min,平均偏差-0.7 mL/min)。
  • relmapirazin测得的GFR独立于CKD分期和种族。
  • 尿中relmapirazin回收率大于或等于碘海醇,未报告严重不良事件。

临床怎么用

  • relmapirazin有望用于即时检测GFR,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The fluorescent compound relmapirazin has been rationally designed for use in point-of-care measurement of glomerular filtration rate (GFR), with attributes including negligible protein binding, negligible metabolites in vivo, negligible tubular secretion, and excellent chemical and photo stability. Twenty-four nonclinical assays were performed in accordance with FDA requirements yielding negligible toxicology concerns. Here, a clinical study was performed to validate relmapirazin as a GFR tracer in patients by comparison to iohexol. This was evaluated in 120 adults at three clinical sites with eGFR values ranging from normal to Stage 4 chronic kidney disease. Relmapirazin and iohexol were administered intravenously in consecutive boluses to each subject and serial blood samples obtained over the subsequent 12 hours. Plasma concentrations were measured and the corresponding plasma GFR for each agent was determined using a standard two-compartment pharmacokinetic assessment. Urine from each subject was collected for the entire 12-hour study period to measure the amount of administered dose appearing in the urine. A near perfect linear regression correlation was observed between the GFRs measured by these two tracers (r2=0.99). Bland-Altman analysis confirmed agreement between these two measures of GFR (limits of agreement -7.0 to +5.6 mL/min; mean of -0.7 mL/min). The GFR determined by relmapirazin was independent of GFR stratification by chronic kidney disease stage, and importantly by race. The percent of the administered relmapirazin dose recovered in the urine was greater than or equal to that of iohexol with no reported severe adverse events. Thus, relmapirazin may be used as a GFR tracer agent in humans.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Dorshow RB, Debreczeny MP, Goldstein SL, et al. Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102). Kidney Int. 2024. PMID: 38964736. doi:10.1016/j.kint.2024.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。